Blood CancerArchives
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Blood Cancer 1 min.
Novel T-cell immunotherapies (chimeric antigen receptor [CAR] T cells and T-cell redirecting bispecific antibodies) are changing the treatment landscape of relapsed or refractory multiple myeloma. In this Review, the European Myeloma Network provides recommendations to optimise both safety and efficacy...
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Blood Cancer 1 min.
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 1 March 2022 and 31 December...
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Blood Cancer 5 min.
The approval of new treatment combinations, including immunomodulatory drugs (IMiD), proteasome inhibitors (PI), and monoclonal antibodies, has significantly improved outcomes for patients with multiple myeloma (MM) over the last decade [1]. However, many patients with MM will relapse, and thus will...
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs
Blood Cancer 1 min.
Maintenance therapy plays a crucial role in prolonging progression-free survival and overall survival in multiple myeloma. Lenalidomide remains the gold standard, as demonstrated in phase 3 trials, consistently showing superior survival compared to observation or placebo. However, both established and...
Exploring health disparities in diagnosing multiple myeloma
Blood Cancer 1 min.
Multiple myeloma (MM) is a plasma cell neoplasm, which accounts for 1–2% of cancers and approximately 17% of hematological malignancies in the United States each year. Fifty percent of patients with symptomatic MM have three or more primary care visits before being referred to a specialist, which...
